• On 26 February 2026, Indivior Pharmaceuticals reported that fourth-quarter 2025 sales rose to US$358 million with net income of US$102 million, reaffirmed its 2026 net revenue outlook of US$1.13 billion to US$1.20 billion, and announced Board authorization for a share repurchase program of up to US$400 million over 18 months.
• The combination of sharply higher quarterly and full-year earnings with a sizeable, cash-funded buyback plan signals management’s confidence in Indivior’s financial position and its ability to return capital to shareholders while continuing to fund its operations.
• Next, we’ll examine how reaffirmed 2026 revenue guidance and the newly authorized US$400 million buyback program could reshape Indivior’s investment narrative.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior, you need to believe long acting injectable therapies for opioid use disorder can keep gaining traction while the company maintains disciplined costs. The sharp step up in 2025 earnings, reaffirmed 2026 revenue outlook of US$1.13 billion to US$1.20 billion, and new US$400 million buyback do not materially change the near term catalyst of SUBLOCADE adoption or the key risk that operating cuts and concentration in a few markets could limit future growth.

The newly authorized US$400 million share repurchase program, funded from available cash over 18 months, is the headline development here. It sits alongside Indivior’s ongoing Indivior Action Agenda, which targets at least US$150 million in annual operating expense savings and a capped 2026 operating budget of US$450 million, reinforcing that capital return is now being pursued at the same time as cost discipline and SUBLOCADE focused investment.

Yet against this backdrop of higher earnings and a larger buyback, investors should be aware of the risk that long acting injectable adoption stalls below expectations and...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and roughly a $353.5 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, a 17% upside to its current price.

Exploring Other Perspectives

While the consensus view anchors on modest revenue growth, the most optimistic analysts were assuming about US$1.3 billion of sales and roughly US$596 million of earnings by 2029, which is a much more upbeat narrative that could look different again after this latest beat and buyback news.

Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.